首页|直肠癌新辅助治疗后近临床完全缓解患者行等待观察策略的预后及肿瘤复发影响因素分析

直肠癌新辅助治疗后近临床完全缓解患者行等待观察策略的预后及肿瘤复发影响因素分析

扫码查看
目的 探讨直肠癌新辅助治疗后近临床完全缓解(near-cCR)患者行等待观察策略的预后及肿瘤复发的影响因素.方法 采用回顾性队列研究方法.收集2013年1月至2017年12月收治的463例(山西省人民医院89例、山西省肿瘤医院374例)低位进展期直肠癌行新辅助治疗患者的临床病理资料;男258例,女205例;年龄为(62±7)岁.患者新辅助治疗后6周接受疗效评估,行等待观察策略的near-cCR患者全面复查后追加辅助化疗6个疗程.观察指标:(1)新辅助治疗情况.(2)影响直肠癌新辅助治疗达到near-cCR行等待观察策略患者肿瘤复发的因素.(3)预后分析.正态分布的计量资料组间比较采用独立样本t检验.计数资料组间比较采用x2检验.等级资料比较采用非参数秩和检验.采用Kaplan-Meier法绘制生存曲线,log-rank检验进行生存分析.多因素分析采用二元logsitic回归模型.结果 (1)新辅助治疗情况.新辅助治疗后达到near-cCR患者136例,其中86例行等待观察策略,50例行腹腔镜直肠癌根治术.86例行等待观察策略患者中,临床分期Ⅱ期29例、Ⅲ期57例;按内镜下肿瘤退缩情况分为瘢痕型27例、溃疡型16例、结节型20例、炎症水肿型23例.(2)影响直肠癌新辅助治疗达到near-cCR行等待观察策略患者肿瘤复发的因素.多因素分析结果显示:年龄是直肠癌新辅助治疗后达到near-cCR行等待观察策略患者肿瘤复发的独立保护因素(优势比=0.88,95%可信区间为0.81~0.97,P<0.05);溃疡型肿瘤分型相对瘢痕型是其独立危险因素(优势比=4.22,95%可信区间为1.01~17.64,P<0.05).(3)预后分析.136例达到near-cCR患者随访时间为65(60~72)个月,86例行等待观察策略患者5年总生存率为84.9%,50例行腹腔镜直肠癌根治术患者5年总生存率为76.0%,两者生存情况比较,差异无统计学意义(x2=1.94,P>0.05).86例行等待观察策略患者中,瘢痕型、溃疡型、结节型、炎症水肿型患者5年总生存率分别为81.5%、75.0%、85.0%、95.7%;4者总生存率比较,差异无统计学意义(x2=3.64,P>0.05).结论 与行腹腔镜直肠癌根治术比较,直肠癌新辅助治疗后达到near-cCR患者行等待观察策略安全、可行.年龄是直肠癌新辅助治疗后达到near-cCR行等待观察策略患者肿瘤复发的独立保护因素;与瘢痕型肿瘤分型比较,溃疡型是其独立危险因素.
Prognosis of rectal cancer patients with wait and see strategy after near clinical complete res-ponse to neoadjuvant therapy and analysis of influencing factors for tumor recurrence
Objective To investigate the prognosis of rectal cancer patients with wait and see strategy after near clinical complete response(near-cCR)to neoadjuvant therapy and influencing factors for tumor recurrence.Methods The retrospective cohort study was conducted.The clinico-pathological data of 463 patients with low advanced rectal cancer who underwent neoadjuvant therapy,including 89 cases in Shanxi Provincial People's Hospital and 374 cases in Shanxi Cancer Hospital,from January 2013 to December 2017 were collected.There were 258 males and 205 females,aged(62±7)years.Patients received efficacy evaluation at 6 weeks after neoadjuvant therapy,in which patients with near-cCR who adhered to wait and see strategy received 6 cycles of additional adjuvant chemotherapy after comprehensive reexaminations.Observation indicators:(1)situations of neoadjuvant therapy;(2)influencing factors for tumor recurrence of rectal cancer patients with wait and see strategy after near-cCR to neoadjuvant therapy;(3)prognostic analysis.Comparison of measurement data with normal distribution between groups was conducted using the independent sample t test.Comparison of count data between groups was conducted using the chi-square test.Comparison of ordinal data was conducted using the nonparameter rank sum test.The Kaplan-Meier method was used to draw survival curve,and the log-rank test was used for survival analysis.The binary logistic regression model was used for univariate and multivariate analyses.Results(1)Situations of neoadjuvant therapy.There were 136 patients achieving near-cCR after neoadjuvant therapy,including 86 cases adhering to wait and see strategy and 50 cases undergoing laparoscopic radical resection of rectal cancer.Of 86 cases with wait and see strategy,29 cases were in clinical stage Ⅱ and 57 cases were in stage Ⅲ.There were 27 cases of scar type,16 cases of ulcer type,20 cases of nodule type,23 cases of inflammatory edema type based on endoscopic tumor regression.(2)Influencing factors for tumor recurrence of rectal cancer patients with wait and see strategy after near-cCR to neoadjuvant therapy.Results of multivariate analysis showed that age was an indepen-dent protective factor for tumor recurrence of rectal cancer patients with wait and see strategy after near-cCR to neoadjuvant therapy(odds ratio=0.88,95%confidence interval as 0.81-0.97,P<0.05).Compared with scar type,the ulcer type was an independent risk factor(odds ratio=4.22,95%confidence interval as 1.01-17.64,P<0.05).(3)Prognostic analysis.All the 136 patients achieving near-cCR were followed up for 65(range,60-72)months.The 5-year overall survival rate was 84.9%of 86 patients with wait and see strategy,versus 76.0%of 50 patients undergoing laparoscopic radical resection of rectal cancer,showing no significant difference between them(x2=1.94,P>0.05).Of 86 patients with wait and see strategy,the 5-year overall survival rate was 81.5%,75.0%,85.0%,95.7%for cases of scar type,ulcer type,nodule type,inflammatory edema type,showing no significant difference among them(x2=3.64,P>0.05).Conclusions Compared with laparoscopic radical resec-tion of rectal cancer,wait and see strategy is safe and feasible for rectal cancer patients after near-cCR to neoadjuvant therapy.Age is an independent protective factor for tumor recurrence of rectal cancer patients with wait and see strategy after near-cCR to neoadjuvant therapy.Compared with scar type,ulcer type is an independent risk factor.

Rectal neoplasmsNeoadjuvant therapyNear clinicalComplete responseWait and seeRadical surgeryRisk factorEfficacy

任晓东、胡震、李耀平、侯生槐、王若雅、李二峰

展开 >

山西省人民医院结直肠肛门外科,太原 030012

山西省肿瘤医院结直肠外科,太原 030013

山西省肿瘤医院内镜室,太原 030013

直肠肿瘤 新辅助治疗 近临床 完全缓解 等待观察策略 根治术 危险因素 疗效

2024

中华消化外科杂志
中华医学会

中华消化外科杂志

CSTPCD北大核心
影响因子:1.899
ISSN:1673-9752
年,卷(期):2024.23(12)